Big Pharma Shifts M&A Focus to Private Biotech Amid Public Market Slowdown

After defying the biggest dealmaking downturn in a decade, Big Pharma is recalibrating its M&A strategy by shifting focus from public companies to smaller, private targets. Major industry players like Bristol Myers Squibb Co. and Abbvie Inc. previously invested heavily, often paying substantial premiums to acquire new blockbuster medicines. However, the heated activity observed in late 2023 has significantly cooled. According to data compiled by Bloomberg, the value of biotech deals has declined by more than 40% year-on-year to approximately $40 billion. This trend persists even as mergers and acquisitions in other sectors experience a resurgence.